» Articles » PMID: 7666914

Azathioprine for Long-term Maintenance of Remission in Autoimmune Hepatitis

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1995 Oct 12
PMID 7666914
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In most patients with autoimmune hepatitis, remission can be maintained with prednisolone, usually in combination with azathioprine, but the majority of patients have a relapse when treatment is stopped and therefore require long-term therapy. Because prolonged corticosteroid therapy may have serious toxic effects, in 1984 we undertook a controlled trial of maintenance therapy with azathioprine alone. None of the 25 patients in that trial had relapses during the follow-up period of one year. We have now followed these 25 patients for 10 years and have treated an additional 47 patients in a similar manner.

Methods: The 72 patients (median age, 47 years; range, 14 to 71) had been in complete remission for at least one year with 5 to 15 mg of prednisolone per day and 1 mg of azathioprine per kilogram per day. The dose of azathioprine was increased to 2 mg per kilogram per day, and the prednisolone was gradually withdrawn. Remission was defined as the absence of symptoms suggestive of a relapse and serum globulin and aspartate aminotransferase concentrations within the normal range, with or without a liver biopsy showing only minimal inflammation.

Results: Sixty patients (83 percent) remained in remission while receiving azathioprine alone for a median of 67 months (range, 12 to 128). Of 48 follow-up liver biopsies in 42 patients, 45 showed inactive or minimal disease, and 3 showed moderate disease (2 after one year of therapy and 1 after eight years). After the prednisolone had been withdrawn, 26 patients lost their cushingoid facies, and 32 patients lost weight (median loss, 6.4 kg; range, 1.5 to 22.3). The most common adverse effect was arthralgia (in 38 patients). With the higher dose of azathioprine, four patients had myelosuppression, defined as a decrease in the leukocyte and platelet counts to less than 4000 and 150,000 per cubic millimeter, respectively. Two of these patients (both with pancytopenia) relapsed when the azathioprine was withdrawn; in the other two, remission was maintained with the resumption of prednisolone. Lymphopenia developed in 32 of 56 patients treated with 2 mg of azathioprine per kilogram per day for more than two years. During follow-up, nine patients died: one of liver failure and eight of causes not directly related to their liver disease.

Conclusions: Many patients with autoimmune hepatitis who have been in complete remission for at least one year with prednisolone and azathioprine can remain in remission with a higher dose of azathioprine alone.

Citing Articles

Hellenic Association for the Study of the Liver (HASL): revised clinical practice guidelines for autoimmune hepatitis.

Dalekos G, Papatheodoridis G, Koskinas J, Goulis I, Rigopoulou E, Tiniakos D Ann Gastroenterol. 2024; 37(6):623-654.

PMID: 39568707 PMC: 11574148. DOI: 10.20524/aog.2024.0924.


Real-world evidence for factors associated with maintenance treatment practices among US adults with autoimmune hepatitis.

Bittermann T, Yagan L, Kathawate R, Weinberg E, Peyster E, Lewis J Hepatology. 2024; 81(2):423-435.

PMID: 38865589 PMC: 11771366. DOI: 10.1097/HEP.0000000000000961.


Management of autoimmune hepatitis induced by hepatitis delta virus.

Gigi E, Lagopoulos V, Liakos A World J Gastroenterol. 2024; 30(8):799-805.

PMID: 38516234 PMC: 10950643. DOI: 10.3748/wjg.v30.i8.799.


The progress of autoimmune hepatitis research and future challenges.

Zhang Y, Zhang D, Chen L, Zhou J, Ren B, Chen H Open Med (Wars). 2023; 18(1):20230823.

PMID: 38025543 PMC: 10655690. DOI: 10.1515/med-2023-0823.


Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells.

Yi Q, Yang J, Wu Y, Wang Y, Cao Q, Wen W Front Immunol. 2023; 14:1204524.

PMID: 37539053 PMC: 10395751. DOI: 10.3389/fimmu.2023.1204524.